Stock Track | Fresenius Medical Care Plunges 6.33% in Pre-market on H2 Earnings Contraction Fears

Stock Track

Aug 04

Fresenius Medical Care AG & Co. KGaA (FMS) shares fell 6.33% in pre-market trading, as investors reacted to the company's second-quarter results and a cautious outlook for the remainder of the year.

Despite reporting adjusted earnings that beat analyst expectations, the German dialysis specialist's reiterated full-year guidance implies a significant earnings contraction in the second half of 2026, according to J.P. Morgan analysts. The bank noted that the company's outlook points to an earnings decline in the mid-teens to mid-20s percentage range in the coming quarters. Additionally, Fresenius Medical Care's quarterly sales of $5.651 billion missed the consensus estimate of $5.720 billion, adding to the negative sentiment.

The pre-market slump was further pressured by a wave of bearish analyst sentiment, with firms including Jefferies, J.P. Morgan, and UBS all maintaining Sell ratings on the stock. The combination of a strong current quarter overshadowed by a weak forward guidance and multiple analyst downgrades drove the sharp decline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1133325559"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1133325559\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1133325559?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 16:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133325559","market":"nz","top_or_hot":-1,"title":"Stock Track | Fresenius Medical Care Plunges 6.33% in Pre-market on H2 Earnings Contraction Fears","media":"Stock Track","content":"<p>Fresenius Medical Care AG & Co. KGaA (FMS) shares fell 6.33% in pre-market trading, as investors reacted to the company's second-quarter results and a cautious outlook for the remainder of the year.</p><p>Despite reporting adjusted earnings that beat analyst expectations, the German dialysis specialist's reiterated full-year guidance implies a significant earnings contraction in the second half of 2026, according to J.P. Morgan analysts. The bank noted that the company's outlook points to an earnings decline in the mid-teens to mid-20s percentage range in the coming quarters. Additionally, Fresenius Medical Care's quarterly sales of $5.651 billion missed the consensus estimate of $5.720 billion, adding to the negative sentiment.</p><p>The pre-market slump was further pressured by a wave of bearish analyst sentiment, with firms including Jefferies, J.P. Morgan, and UBS all maintaining Sell ratings on the stock. The combination of a strong current quarter overshadowed by a weak forward guidance and multiple analyst downgrades drove the sharp decline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Fresenius Medical Care Plunges 6.33% in Pre-market on H2 Earnings Contraction Fears</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Fresenius Medical Care Plunges 6.33% in Pre-market on H2 Earnings Contraction Fears\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-04 16:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Fresenius Medical Care AG & Co. KGaA (FMS) shares fell 6.33% in pre-market trading, as investors reacted to the company's second-quarter results and a cautious outlook for the remainder of the year.</p><p>Despite reporting adjusted earnings that beat analyst expectations, the German dialysis specialist's reiterated full-year guidance implies a significant earnings contraction in the second half of 2026, according to J.P. Morgan analysts. The bank noted that the company's outlook points to an earnings decline in the mid-teens to mid-20s percentage range in the coming quarters. Additionally, Fresenius Medical Care's quarterly sales of $5.651 billion missed the consensus estimate of $5.720 billion, adding to the negative sentiment.</p><p>The pre-market slump was further pressured by a wave of bearish analyst sentiment, with firms including Jefferies, J.P. Morgan, and UBS all maintaining Sell ratings on the stock. The combination of a strong current quarter overshadowed by a weak forward guidance and multiple analyst downgrades drove the sharp decline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FMS","symbol_name":"费森尤斯医疗","start_time":0,"source_url":"","article_id":"1133325559","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133325559","pubTimestamp":1785830788,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Fresenius Medical Care AG & Co. KGaA (FMS) shares fell 6.33% in pre-market trading, as investors reacted to the company's second-quarter results and a cautious outlook for the remainder of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FMS":"费森尤斯医疗"},"translate_title":"股票跟踪 | 由于担心下半年盈利萎缩，费森尤斯医疗保健公司盘前暴跌 6.33%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FMS":1},"content_text":"Fresenius Medical Care AG & Co. KGaA (FMS) shares fell 6.33% in pre-market trading, as investors reacted to the company's second-quarter results and a cautious outlook for the remainder of the year.Despite reporting adjusted earnings that beat analyst expectations, the German dialysis specialist's reiterated full-year guidance implies a significant earnings contraction in the second half of 2026, according to J.P. Morgan analysts. The bank noted that the company's outlook points to an earnings decline in the mid-teens to mid-20s percentage range in the coming quarters. Additionally, Fresenius Medical Care's quarterly sales of $5.651 billion missed the consensus estimate of $5.720 billion, adding to the negative sentiment.The pre-market slump was further pressured by a wave of bearish analyst sentiment, with firms including Jefferies, J.P. Morgan, and UBS all maintaining Sell ratings on the stock. The combination of a strong current quarter overshadowed by a weak forward guidance and multiple analyst downgrades drove the sharp decline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}